FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988870869> ?p ?o ?g. }

• W1988870869 endingPage "140" @default.
• W1988870869 startingPage "137" @default.
• W1988870869 abstract "Tabled 1KEY TEACHING POINTS•Flecainide overdose is difficult to treat because of the drug’s high oral bioavailability (90%), high volume of distribution, long half-life (up to 23 hours), poor ability to be dialyzed, lack of an antidote, and rapid onset of shock and arrhythmias (as early as 30 minutes after ingestion).•Initial management consists of careful monitoring of vital signs with admission to the intensive care unit, telemetry, administration of activated charcoal, repletion of electrolytes, aggressive use of IV fluids and hypertonic sodium bicarbonate, and the potential use of IV fat emulsion.•Flecainide overdose can rapidly cause arrhythmias and shock, which if refractory to medications (antiarrhythmics, vasopressors) and electricity (pacing, cardioversion) will require mechanical circulatory support, most commonly venoarterial extracorporeal membrane oxygen (VA-ECMO). We recommend early evaluation of the patient by the ECMO team because VA-ECMO, even of sustained duration, appears to be a lifesaving intervention for refractory cardiogenic shock due to flecainide overdose. Open table in a new tab Ms. A is a 33-year-old woman with a history of depression and polysubstance use disorder who presented to our hospital after transfer from another facility’s emergency department after an intentional flecainide overdose. Her spouse heard a “thud” at approximately 5 AM on the day of admission. He found her unconscious after she had ingested 12 tablets of 150-mg flecainide originally prescribed to him. She was taken to another facility, where she was found to be in a wide complex rhythm with a heart rate of 63 (Figure 1) and blood pressure of 69/29. She was given 1 L normal saline, started on 2 μg/kg/min of dobutamine, and electively intubated for airway protection in the setting of altered mental status. Promptly after intubation, she developed pulseless ventricular tachycardia (VT), which necessitated initiation of advanced cardiac life support. During this process, she received 11 ampules of sodium bicarbonate, was started on intravenous (IV) isotonic sodium bicarbonate at 150 cc/h, and given a 500-cc bolus of IV fat emulsion. At this point, return of spontaneous circulation was obtained, and the dobutamine infusion was stopped. On arrival to our hospital, the patient was noted to be in an irregular, wide complex tachycardia; otherwise her physical examination was unremarkable. Result of laboratory studies were notable for Na 160, K 3.0, HCO3 50, Cr 0.78, and iCal 0.77. Her blood gas values were pH 7.71, Paco2 48, and Pao2 166 on 100% Fio2. During the early part of her course, she received another 11 ampules of bicarbonate, and her bicarbonate gtt was uptitrated to 300 cc/h. With this treatment, her ECG stabilized to a junctional rhythm at 82 bpm with intermittent runs of hemodynamically stable, slow VT. Given her high pH, additional bicarbonate was not administered. She was given another 1000 cc of IV fat emulsion. During the day she became bradycardic, with heart rates into the 40s, and was refractory to atropine. Despite the development of atrial fibrillation with frequent premature ventricular complexes and an extremely prolonged QTc of approximately 700 ms (Figure 2), her hemodynamic status remained stable on vasopressin 0.04 units and phenylephrine 100 μg/min. Approximately 14 hours after arrival to our hospital, she became more hemodynamically unstable and was refractory to multiple defibrillations. Her rhythm twice devolved into pulseless electrical activity but recovered each time after advanced cardiac life support to a monomorphic VT. At this time, the decision was made to cannulate for venoarterial extracorporeal membrane oxygen (VA-ECMO) support for refractory VT and shock. During cannulation, her hemodynamics were supported with a norepinephrine gtt and IV pushes of epinephrine. Initial rates of VA-ECMO were approximately 4 L/min. During her time on VA-ECMO, the patient received a total of 8 units of packed red blood cells and 8 units of fresh frozen plaza, believed secondary to blood loss. Approximately 72 hours after cannulation, her ECG normalized to normal sinus rhythm with first-degree AV block and nonspecific ST/TW changes (Figure 3). She was weaned and decannulated from VA-ECMO. Upon decannulation, she was weaned off sedation and extubated uneventfully before transfer to a psychiatric facility for further treatment of her depression. Approximately 2 months after discharge, her neurologic function is intact.Figure 3ECG before venoarterial extracorporeal membrane oxygen (VA-ECMO) decannulation.View Large Image Figure ViewerDownload (PPT) We report the longest successful use of VA-ECMO for treatment of flecainide overdose and the first successful use of VA-ECMO for flecainide overdose in the United States. Flecainide is a class IC antiarrhythmic drug, a class of medications whose overdose is associated with approximately 20% mortality.1Cheung I. Man C. Review on flecainide poisoning.Hong Kong J Emerg Med. 2002; 9: 150-153Google Scholar Flecainide causes rate-dependent slowing of the fast sodium current INa during phase 0 of the cardiac action potential as well as inhibition of the rectifier potassium current IKr during phase 3.2Rognoni A. Bertolazzi M. Peron M. et al.Electrocardiographic changes in a rare case of flecainide poisoning: a case report.Cases J. 2009; 2: 9137Crossref PubMed Scopus (7) Google Scholar, 3Lovecchio F. Berlin R. Brubacher J.R. Sholar J.B. Hypertonic sodium bicarbonate in an acute flecainide overdose.Am J Emerg Med. 1998; 16: 534-537Abstract Full Text PDF PubMed Scopus (28) Google Scholar, 4Timperley J. Mitchell A.R. Brown P.D. West N.E. Flecainide overdose—support using an intra-aortic balloon pump.BMC Emerg Med. 2005; 5: 10Crossref PubMed Scopus (16) Google Scholar Flecainide overdose is difficult to treat because of the drug’s high oral bioavailability (90%), high volume of distribution (8–9 L/kg), long half- life (up to 23 hours), poor ability to be dialyzed, lack of an antidote, and rapid onset of shock and arrhythmias (as early as 30 minutes after ingestion).1Cheung I. Man C. Review on flecainide poisoning.Hong Kong J Emerg Med. 2002; 9: 150-153Google Scholar, 5Devin R. Garrett P. Anstey C. Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy.Emerg Medicine Austr. 2007; 19: 155159Google Scholar, 6Gotz D. Pohle S. Barckow D. Primary and secondary detoxification in severe flecainide intoxication.Intensive Care Med. 1991; 17: 181184Crossref Scopus (17) Google Scholar Flecainide overdose is relatively rare, and the literature on its treatment is limited to animal studies and case reports. Initial management consists of careful monitoring of vital signs, telemetry, aggressive IV fluids, repletion of electrolytes, and admission to the intensive care unit. Because of flecainide’s high oral bioavailability, treatment may include gastric lavage if the patient presents within 1 hour of ingestion and activated charcoal regardless of the time to presentation.1Cheung I. Man C. Review on flecainide poisoning.Hong Kong J Emerg Med. 2002; 9: 150-153Google Scholar, 6Gotz D. Pohle S. Barckow D. Primary and secondary detoxification in severe flecainide intoxication.Intensive Care Med. 1991; 17: 181184Crossref Scopus (17) Google Scholar Our patient did not receive gastric lavage because she presented to our hospital more than 1 hour after ingestion. Multiple studies support the early and ample use of hypertonic sodium bicarbonate,2Rognoni A. Bertolazzi M. Peron M. et al.Electrocardiographic changes in a rare case of flecainide poisoning: a case report.Cases J. 2009; 2: 9137Crossref PubMed Scopus (7) Google Scholar, 3Lovecchio F. Berlin R. Brubacher J.R. Sholar J.B. Hypertonic sodium bicarbonate in an acute flecainide overdose.Am J Emerg Med. 1998; 16: 534-537Abstract Full Text PDF PubMed Scopus (28) Google Scholar, 5Devin R. Garrett P. Anstey C. Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy.Emerg Medicine Austr. 2007; 19: 155159Google Scholar, 7Goldman M.J. Mowry J.B. Kirk M.A. Sodium bicarbonate to correct widened QRS in a case of flecainide overdose.J Emerg Med. 1997; 15: 183-186Abstract Full Text PDF PubMed Scopus (38) Google Scholar which has been reported in doses up to 350 mEq5Devin R. Garrett P. Anstey C. Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy.Emerg Medicine Austr. 2007; 19: 155159Google Scholar for a goal pH of 7.5–7.55 or a goal QRS width <160 ms.1Cheung I. Man C. Review on flecainide poisoning.Hong Kong J Emerg Med. 2002; 9: 150-153Google Scholar A high sodium concentration is theorized to antagonize flecainide at sodium channels on cardiac myocytes.5Devin R. Garrett P. Anstey C. Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy.Emerg Medicine Austr. 2007; 19: 155159Google Scholar Flecainide is a weak base, and alkalization of the blood may decrease the ionized form of flecainide, which binds sodium channels.2Rognoni A. Bertolazzi M. Peron M. et al.Electrocardiographic changes in a rare case of flecainide poisoning: a case report.Cases J. 2009; 2: 9137Crossref PubMed Scopus (7) Google Scholar, 7Goldman M.J. Mowry J.B. Kirk M.A. Sodium bicarbonate to correct widened QRS in a case of flecainide overdose.J Emerg Med. 1997; 15: 183-186Abstract Full Text PDF PubMed Scopus (38) Google Scholar Recent literature supports the use of IV fat emulsion (100 mL or 1.5 mL/kg of 20% IV fat emulsion) to decrease the volume of distribution of fat-soluble medications such as flecainide.8Ellsworth H. Stellpflug S.J. Cole J.B. Dolan J.A. Harris C.R. A life-threatening flecainide overdose treated with intravenous fat emulsion.Pacing Clin Electrophysiol. 2013; 36: e87-e89Crossref PubMed Scopus (29) Google Scholar Flecainide can induce rapid arrhythmias, particular bradyarrhythmias, heart block, VT, ventricular fibrillation, and pulseless electrical activity.5Devin R. Garrett P. Anstey C. Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy.Emerg Medicine Austr. 2007; 19: 155159Google Scholar, 9Kolecki P.F. Curry S.C. Poisoning by sodium channel blocking agents.Crit Care Clin. 1997; 13: 829-848Abstract Full Text Full Text PDF PubMed Scopus (87) Google Scholar These rhythms may be refractory to electrical cardioversion.8Ellsworth H. Stellpflug S.J. Cole J.B. Dolan J.A. Harris C.R. A life-threatening flecainide overdose treated with intravenous fat emulsion.Pacing Clin Electrophysiol. 2013; 36: e87-e89Crossref PubMed Scopus (29) Google Scholar, 10Bauman J.L. Gallastegui J. Tanenbaum S.R. Hariman R.J. Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine.Chest. 1987; 92: 573-575Crossref PubMed Scopus (16) Google Scholar, 11Siegers A. Board P.N. Amiodarone used in successful resuscitation after near-fatal flecainide overdose.Resuscitation. 2002; 53: 105-108Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar Treatment options include atropine or a pacemaker for bradyarrhythmias, although capture may be difficult.10Bauman J.L. Gallastegui J. Tanenbaum S.R. Hariman R.J. Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine.Chest. 1987; 92: 573-575Crossref PubMed Scopus (16) Google Scholar, 12Auzinger G.M. Scheinkestel C.D. Successful extracorporeal life support in a case of severe flecainide intoxication.Crit Care Med. 2001; 29: 887-890Crossref PubMed Scopus (53) Google Scholar, 13Corkeron M.A. van Heerden P.V. Newman S.M. Dusci L. Extracorporeal circulatory support in near-fatal flecainide overdose.Anaesth Intens Cre. 1999; 27: 405-408PubMed Google Scholar For tachyarrhythmias, there have been reports of success with lidocaine for sustained VT, although the theoretical risk of interaction between class IB and IC agents remains high.14Hanley N.A. Bourke J.P. Gascoigne A.D. Survival in a case of life-threatening flecainide overdose.Intensive Care Med. 1998; 24: 740-742Crossref PubMed Scopus (15) Google Scholar Another report from Germany reported success with amiodarone for treatment of refractory ventricular fibrillation,11Siegers A. Board P.N. Amiodarone used in successful resuscitation after near-fatal flecainide overdose.Resuscitation. 2002; 53: 105-108Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar and a separate review suggested antitachycardia treatment with a pacemaker or isoproterenol if needed.1Cheung I. Man C. Review on flecainide poisoning.Hong Kong J Emerg Med. 2002; 9: 150-153Google Scholar Because of flecainide’s ability to cause both bradyarrhythmias and tachyarrhythmias, clinicians should be cautious when monitoring for therapeutic interventions causing overcompensation (ie, bradyarrhythmia becoming a tachyarrhythmia and vice versa). Shock can develop rapidly in flecainide overdose due to chronotropic and inotropic incompetence.2Rognoni A. Bertolazzi M. Peron M. et al.Electrocardiographic changes in a rare case of flecainide poisoning: a case report.Cases J. 2009; 2: 9137Crossref PubMed Scopus (7) Google Scholar, 4Timperley J. Mitchell A.R. Brown P.D. West N.E. Flecainide overdose—support using an intra-aortic balloon pump.BMC Emerg Med. 2005; 5: 10Crossref PubMed Scopus (16) Google Scholar Use of vasopressors such as phenylephrine is difficult because of reflex bradycardia. Use of inotropic agents may be limited by the rate-dependent effect of flecainide as well as the risk of precipitating ventricular arrhythmias. There have been reports of use of assist devices to support individuals through flecainide-induced cardiogenic shock. Timperley et al4Timperley J. Mitchell A.R. Brown P.D. West N.E. Flecainide overdose—support using an intra-aortic balloon pump.BMC Emerg Med. 2005; 5: 10Crossref PubMed Scopus (16) Google Scholar published the first and only successful use of an intra-aortic balloon pump for a patient treated as having cardiogenic shock from a myocardial infarction, which was diagnosed after discharge as a flecainide overdose. In the first description of VA-ECMO for flecainide overdose, Yasui et al15Yasui R.K. Culclasure T.F. Kaufman D. Freed C.R. Flecainide overdose: is cardiopulmonary support the treatment?.Ann Emerg Med. 1997; 29: 680-682Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar showed that 10 hours of VA-ECMO lowered flecainide levels (peak 5.45 μg/mL) after ingestion of an unknown quantity of medication. However, care was withdrawn after the patient was found to have poor neurologic function. The report argued for the use of VA-ECMO in shock to maintain perfusion to the liver, which sustains flecainide clearance. The first successful report using VA-ECMO was in 1999 from Australia, where VA-ECMO was used for 30 hours for a 4-g ingestion.13Corkeron M.A. van Heerden P.V. Newman S.M. Dusci L. Extracorporeal circulatory support in near-fatal flecainide overdose.Anaesth Intens Cre. 1999; 27: 405-408PubMed Google Scholar The patient survived to discharge with normal neurologic function. In the second successful report, also from Australia, VA-ECMO was used for 26 hours for a 6-g ingestion, and the authors argue that VA-ECMO time >36 hours is unlikely to be required.12Auzinger G.M. Scheinkestel C.D. Successful extracorporeal life support in a case of severe flecainide intoxication.Crit Care Med. 2001; 29: 887-890Crossref PubMed Scopus (53) Google Scholar The use of VA-ECMO in these reports was complicated by bleeding and hematoma formation requiring blood products,12Auzinger G.M. Scheinkestel C.D. Successful extracorporeal life support in a case of severe flecainide intoxication.Crit Care Med. 2001; 29: 887-890Crossref PubMed Scopus (53) Google Scholar, 13Corkeron M.A. van Heerden P.V. Newman S.M. Dusci L. Extracorporeal circulatory support in near-fatal flecainide overdose.Anaesth Intens Cre. 1999; 27: 405-408PubMed Google Scholar, 15Yasui R.K. Culclasure T.F. Kaufman D. Freed C.R. Flecainide overdose: is cardiopulmonary support the treatment?.Ann Emerg Med. 1997; 29: 680-682Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar similar to our experience. To our knowledge, this is the first case report of VA-ECMO time >36 hours for treatment of flecainide overdose and the first successful use of VA-ECMO for flecainide overdose in the United States. This reports shows that a longer duration of VA-ECMO (up to 72 hours) may be required for flecainide overdose. A longer duration of VA-ECMO can lead to survival with resulting normal neurologic function. In treatment of flecainide overdose, our review of the literature suggests that initial care should include careful monitoring of vital signs with admission to the intensive care unit, administration of activated charcoal, repletion of electrolytes, aggressive use of IV fluids and hypertonic sodium bicarbonate, and the potential use of IV fat emulsion. Flecainide overdose can rapidly cause arrhythmias and shock, which if refractory to medications (antiarrhythmics, vasopressors) and electricity (pacing, cardioversion) will require mechanical circulatory support, most commonly VA-ECMO. We recommend early evaluation of the patient by the ECMO team because VA-ECMO, even of sustained duration, appears to be a lifesaving intervention for refractory cardiogenic shock due to flecainide overdose." @default.
• W1988870869 created "2016-06-24" @default.
• W1988870869 creator A5032837530 @default.
• W1988870869 creator A5057016218 @default.
• W1988870869 creator A5068688393 @default.
• W1988870869 creator A5089120659 @default.
• W1988870869 date "2015-05-01" @default.
• W1988870869 modified "2023-10-03" @default.
• W1988870869 title "Successful treatment of flecainide overdose with sustained mechanical circulatory support" @default.
• W1988870869 cites W1519149290 @default.
• W1988870869 cites W1826369248 @default.
• W1988870869 cites W1986756088 @default.
• W1988870869 cites W2006562248 @default.
• W1988870869 cites W2034831040 @default.
• W1988870869 cites W2043681979 @default.
• W1988870869 cites W2046794710 @default.
• W1988870869 cites W2064076422 @default.
• W1988870869 cites W2064756908 @default.
• W1988870869 cites W2091752504 @default.
• W1988870869 cites W2130070881 @default.
• W1988870869 cites W2150282986 @default.
• W1988870869 cites W2156113804 @default.
• W1988870869 cites W2771525083 @default.
• W1988870869 cites W40217535 @default.
• W1988870869 doi "https://doi.org/10.1016/j.hrcr.2015.01.003" @default.
• W1988870869 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5418611" @default.
• W1988870869 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28491532" @default.
• W1988870869 hasPublicationYear "2015" @default.
• W1988870869 type Work @default.
• W1988870869 sameAs 1988870869 @default.
• W1988870869 citedByCount "7" @default.
• W1988870869 countsByYear W19888708692019 @default.
• W1988870869 countsByYear W19888708692020 @default.
• W1988870869 countsByYear W19888708692021 @default.
• W1988870869 countsByYear W19888708692022 @default.
• W1988870869 crossrefType "journal-article" @default.
• W1988870869 hasAuthorship W1988870869A5032837530 @default.
• W1988870869 hasAuthorship W1988870869A5057016218 @default.
• W1988870869 hasAuthorship W1988870869A5068688393 @default.
• W1988870869 hasAuthorship W1988870869A5089120659 @default.
• W1988870869 hasBestOaLocation W19888708691 @default.
• W1988870869 hasConcept C126322002 @default.
• W1988870869 hasConcept C164705383 @default.
• W1988870869 hasConcept C177713679 @default.
• W1988870869 hasConcept C2779161974 @default.
• W1988870869 hasConcept C2779837460 @default.
• W1988870869 hasConcept C42219234 @default.
• W1988870869 hasConcept C71924100 @default.
• W1988870869 hasConcept C72859922 @default.
• W1988870869 hasConceptScore W1988870869C126322002 @default.
• W1988870869 hasConceptScore W1988870869C164705383 @default.
• W1988870869 hasConceptScore W1988870869C177713679 @default.
• W1988870869 hasConceptScore W1988870869C2779161974 @default.
• W1988870869 hasConceptScore W1988870869C2779837460 @default.
• W1988870869 hasConceptScore W1988870869C42219234 @default.
• W1988870869 hasConceptScore W1988870869C71924100 @default.
• W1988870869 hasConceptScore W1988870869C72859922 @default.
• W1988870869 hasIssue "3" @default.
• W1988870869 hasLocation W19888708691 @default.
• W1988870869 hasLocation W19888708692 @default.
• W1988870869 hasLocation W19888708693 @default.
• W1988870869 hasLocation W19888708694 @default.
• W1988870869 hasLocation W19888708695 @default.
• W1988870869 hasLocation W19888708696 @default.
• W1988870869 hasOpenAccess W1988870869 @default.
• W1988870869 hasPrimaryLocation W19888708691 @default.
• W1988870869 hasRelatedWork W1984162378 @default.
• W1988870869 hasRelatedWork W1985548875 @default.
• W1988870869 hasRelatedWork W2041185186 @default.
• W1988870869 hasRelatedWork W2059148215 @default.
• W1988870869 hasRelatedWork W2065279192 @default.
• W1988870869 hasRelatedWork W2071584338 @default.
• W1988870869 hasRelatedWork W2078913520 @default.
• W1988870869 hasRelatedWork W2091340328 @default.
• W1988870869 hasRelatedWork W2898458062 @default.
• W1988870869 hasRelatedWork W4293075678 @default.
• W1988870869 hasVolume "1" @default.
• W1988870869 isParatext "false" @default.
• W1988870869 isRetracted "false" @default.
• W1988870869 magId "1988870869" @default.
• W1988870869 workType "article" @default.